Table 4.
The change of CD4 count and HIV viral load in patients with HIV and concomitant CRC according to antiviral regimens (n = 66)
| Baseline | M1 | M3 | M6 | ||
|---|---|---|---|---|---|
| DTG/3TC/TDF (group I) n = 20 | CD4 (cells/ul) | 368.35 (195–980) | 319.2 (164–624) | 280.6 (146–578) | 247.5 (150–456) |
| CD4/CD8 ratio | 0.91 (0.19–2.87) | 0.72 (0.22–2.22) | 0.69 (0.3–1.64) | 0.69 (0.5–1.01) | |
| HIV viral load (copies/ml) | |||||
| ≤ 20 | 18 | 19 | 20 | 20 | |
| 20–1000 | 1 | 1 | 1 | 0 | |
| > 1000 | 1 | 0 | 0 | 0 | |
| DTG/ABT (group II) n = 24 | CD4 (cells/ul) | 272.71 (83–757) | 262.29 (108–494) | 267.25 (210–513) | 301 (167–337) |
| CD4/CD8 ratio | 0.75 (0.14–2.86) | 0.53 (0.11–0.8) | 0.52 (0.2–1.4) | 0.67 (0.2–1.5) | |
| HIV viral load (copies/ml) | |||||
| ≤ 20 | 19 | 22 | 24 | 24 | |
| 20–1000 | 1 | 1 | 0 | 0 | |
| > 1000 | 4 | 1 | 0 | 0 | |
| BIC/TAF/FTC (group III) n = 22 | CD4 (cells/ul) | 315.14 (85–980) | 404.27 (111–479) | 388.91 (86–577) | 327.38 (82–612) |
| CD4/CD8 ratio | 0.60 (0.08–1.68) | 0.98 (0.09–2.86) | 0.92 (0.21–1.7) | 0.76 (0.2–1.29) | |
| HIV viral load (copies/ml) | |||||
| ≤ 20 | 17 | 20 | 20 | 21 | |
| 20–1000 | 2 | 1 | 1 | 1 | |
| > 1000 | 3 | 1 | 1 | 0 | |
CRC colorectal cancer
DTG/3TC/TDF = dolutegravir/lamivudine/tenofovir
DTG/ABT = dolutegravir/albuvirtide
BIC/TAF/FTC = bictegravir/tenofovir alafenamide/emtricitabine
M1 = the first month ± 1 week
M3 = the third month ± 1 week
M6 = the sixth month ± 1 week